Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Area of Science:

• Neuroscience
• Clinical Neurology
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Rasagiline is a selective monoamine oxidase B (MAO-B) inhibitor with potential neuroprotective properties.
• Investigating novel therapeutic targets for ALS is crucial.

Purpose of the Study:

• To evaluate the efficacy of rasagiline in slowing disease progression in ALS patients.
• To assess the safety and tolerability of rasagiline in this population.
• To explore rasagiline's effect on biomarkers and survival.

Main Methods:

• A randomized, double-blind, placebo-controlled trial involving 80 ALS participants.
• Participants were randomized 3:1 to receive 2 mg/day rasagiline or placebo.
• Primary outcome: ALSFRS-R slope; Secondary outcomes: vital capacity, survival, biomarkers, adverse events.

Main Results:

• No significant difference in the 12-month ALSFRS-R slope between rasagiline and control groups.
• Rasagiline did not demonstrate drug-target engagement via biomarkers.
• The drug was well-tolerated with no serious adverse events reported.

Conclusions:

• Rasagiline did not alter ALS disease progression over 12 months.
• The study did not support rasagiline as a treatment for ALS.
• Further research into neuroprotective agents for ALS is warranted.